Ventripoint Joint Venture Begins Device Certification For Use In Covid Patients In China

Ventripoint Diagnostics (TSXV: VPT) is progressing with its joint venture partner in China. This morning the firm revealed that its partner, Yutian Medical Shanghai, has begun actively working with regulatory bodies to have its device certified for use with COVID patients.

The certification for this application follows Chinese guidelines being modified for the treatment and diagnosis of COVID-10 patients in the country, which now require monitoring of right-ventricular function by non-invasive techniques. Given the suitability of the QMS device (the rebranded name for VMS in the region) for such an application, the joint venture has begun the certification process.

To date, the venture has been successful in placing the devices in intensive care units, with further demand anticipated to meet potential future needs as the hospital deals with COVID. The application of the devices for this purpose as a result substantially expands the potential market for the device, beyond just that of cardiovascular disease.

Ventripoint Diagnostics last traded at $0.53 on the TSX Venture.


FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Silver Catch-Up Time: Why the 7:1 Gold-Silver Ratio Matters [Summa-Silver47 Merger]

$8,900 Gold? Why Silver and Miners Could Outperform | Ronald-Peter Stöferle

Gold Could Easily Double Again in This Run!? | Dan Wilton – First Mining Gold

Recommended

PTX Metals Intersects 97 Metres Of Mineralization In Latest Assay Results At W2

Goliath Resources Identifies 26.47 Metre Interval Of Visible Gold In Hole GD-22-64

Related News

VentriPoint Diagnostics: Corporate Overview

VentriPoint Diagnostics Ltd. (TSXV: VPT) is a small-cap medical device company that develops and commercializes...

Saturday, June 5, 2021, 05:25:00 PM

Ventripoint Diagnostics: Using AI To Analyze The Heart – The Daily Dive feat George Adams

Today on the Daily Dive, our host Cassandra Leah sits down with George Adams, Executive...

Wednesday, April 21, 2021, 01:30:00 PM

Ventripoint Sees First Commercial Sales In China Through Joint Venture

Ventripoint Diagnostics (TSXV: VPT) this morning issued a brief press release related to its joint...

Tuesday, March 2, 2021, 08:25:53 AM

Ventripoint Diagnostics Installs Whole Heart Analysis Device At Leading European Hospital

Ventripoint Diagnostics (TSXV: VPT) this morning announced that its latest version of its whole heart...

Monday, September 28, 2020, 09:09:32 AM

The Future Of 3D Heart Modeling – The Daily Dive feat George Adams

George Adams, CEO of Ventripoint Diagnostics (TSXV: VPT) joins our host Cassandra Leah today to...

Thursday, November 19, 2020, 01:00:00 PM